Tweets
Peyton et al.: 4 multimorbidity patterns in RA
-Mental health and subst abuse
-Metabolic
-CV
-Chronic pain
All associated with different sets of biomarkers.
Some are very specific of one profile while others are widespread across profiles.
@RheumNow #ACR23 ABST1631 https://t.co/VqCrLI3oyy
Aurelie Najm ( View Tweet )
2 years 3 months ago
Ultrasound (and specifically intima-media thickness) might not just be for diagnosis in GCA - it might be a GCA disease activity measure for monitoring:
- improves over time
- increases with flares
Valentin Schaefer #ACR23 ABST1649 @RheumNow https://t.co/QWdIVGrHbn
David Liew @drdavidliew ( View Tweet )
2 years 3 months ago
Ross et al. Ultrasound assessed Optic nerve sheath measurement in GCA. Previously shown increased in GCA. Here decreases with treatment shown in 9 patients Abstr#1650 #ACR23 @RheumNow https://t.co/fcrS4tT6U0 https://t.co/ylnPKzdUe0
Richard Conway ( View Tweet )
2 years 3 months ago
In PS-matched study, no significant difference in respiratory hospitalisation or death between RA-ILD patients on non-TNFi/JAKi vs. TNFi. This finding does not support systematic avoidance of TNFi in RA-ILD, England B Abst#1582 #ACR23 #ACRBest @RheumNow https://t.co/1zVjMWNZZS https://t.co/d8TRIvGaIe
Dr. Antoni Chan ( View Tweet )
2 years 3 months ago
Fate of ANA+/UCTD
A#1449 #ACR23 @RheumNow
207 asymptomatic ANA+ or UCTD followed
- <10% progress to SARD, 90% did not
Progression to SLE (11 pt), Sjo (5), SSc (3), RA (1)
Progressors to SLE: arthritis (91%), low compl (45%), alopecia (36%), ulcers (27%) - milder manifestations
Eric Dein ( View Tweet )
2 years 3 months ago
Abst#1583 SMART study: Split dose qwk MTX (10 mg QAM, 15 mg QPM) may have better efficacy compared to 25 mg single dose qwk MTX. RCT 253 RA patients: split dose had better DAS score, less likely to add other DMARDS, but slight⬆️in LFTs. #Plenary #ACR23 @rheumnow #ACRbest
TheDaoIndex @KDAO2011 ( View Tweet )
2 years 3 months ago
Visit RheumNow's Booth at #ACR23
https://t.co/7HuNpWtf0M https://t.co/INtMGvEkA3
Dr. John Cush @RheumNow ( View Tweet )
2 years 3 months ago
Evidence of window of opportunity concept in PsA. Certainly >52 weeks delay associates with worse outcomes. <12 weeks and 12-52 weeks similar. Abstr#1641 #ACR23 @RheumNow https://t.co/fMb3D9zl8B https://t.co/rHu29Eflo0
Richard Conway ( View Tweet )
2 years 3 months ago
FDG-PET uptake at baseline in GCA predicts future risk of future thoracic aneurysm
In print here: https://t.co/2SQm18y6zP
Could this help stratify aneurysmal screening?
#ACR23 ABST1647 @RheumNow https://t.co/p1Dhkm2WTX
David Liew @drdavidliew ( View Tweet )
2 years 3 months ago
It's OK to use TNFi in RA-ILD!
VA study 1000+ pts using Target Trial Emulation framework: TNFi vs nonTNFi biologics/JAKi followed for 3 years. NO differences in respiratory hospitalizations or deaths or all cause mortality. abst#1582 #ACR23 #ACRbest @rheumnow https://t.co/aI2SmMrLPE
TheDaoIndex @KDAO2011 ( View Tweet )
2 years 3 months ago
Wolfgang Schmidt presenting @eular_org large vessel vasculitis imaging recommendations at #ACR23, acknowledging @ACRheum on the way.
Great to see a master (& a new ACR Master) navigate with clarity, uniting different sides of the Atlantic.
@RheumNow https://t.co/hyAcX8GSWf
David Liew @drdavidliew ( View Tweet )
2 years 3 months ago
What do we see in GCA, with serial PET/CT after five years?
In this Australian cohort:
cranial uptake disappears
extra-cranial uptake sometimes emerges (but not for pts on DMARDs)
Still understanding the trajectory of smouldering activity
@tonysammel #ACR23 ABST1645 @RheumNow https://t.co/mKB3mjBuBt
David Liew @drdavidliew ( View Tweet )
2 years 3 months ago
